GlassScriptPhysician profile
Julia G Burden
NPI 1619107901
$1,100.03
in general payments reported to CMS, 2019-2025
10 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.06 · 2020: $64.94 · 2021: $126 · 2022: $314 · 2023: $257 · 2024: $105 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $559.42 | 2022-2025 | |
| Pfizer INC. | $222.13 | 2019-2023 | |
| Pierre Fabre Pharmaceuticals, INC. | $86.77 | 2021-2025 | Hemangeol |
| Novartis Pharmaceuticals Corporation | $80.36 | 2021-2023 | |
| Regeneron Pharmaceuticals, INC. | $59.28 | 2022-2023 | Dupixent |
| Regeneron Healthcare Solutions, INC. | $34.07 | 2023-2025 | Dupixent |
| Incyte Corporation | $20.59 | 2021 | |
| Lilly USA, LLC | $19.12 | 2020 | |
| Krystal Biotech INC | $14.62 | 2023 | Vyjuvek |
| Organon LLC | $3.67 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Burden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.